RESULTAT DU VOTE DES RESOLUTIONS PRESENTEES A L’ASSEMBLEE GENERALE ORDINAIRE ANNUELLE

Equasens a tenu son Assemblée Générale Ordinaire Annuelle le 25 juin 2026 avec un quorum de 87,8% (13.021.748 actions votantes sur 14.832.456 ayant droit de vote) et a approuvé les comptes sociaux et consolidés de l’exercice 2025. Le communiqué détaille le résultat des votes de résolutions proposées par le Conseil d’Administration, sans indication chiffrée d’impact financier immédiat. Prochain jalon: publication du chiffre d’affaires S1 2026 le 30 juillet 2026 (après bourse) et des résultats S1 2026 le 28 septembre 2026 (avant bourse).

Analysis

This is a non-event for fundamentals: the vote outcome mainly removes a governance overhang and confirms the board still has a functioning shareholder base, but it does not alter revenue, margins, or capital allocation. For a small-cap healthcare software name like EQS, that means the stock should trade more on booking cadence and renewal visibility than on AGM optics.

The real catalyst is the July 30 top-line update, because healthcare IT vendors tend to re-rate on evidence of deferred-project conversion rather than on annual meeting mechanics. If management has been holding up through a slow procurement environment, a decent S1 print would support multiple expansion; if not, the market will quickly infer elongating sales cycles and push out growth expectations into 2027.

Second-order, the lack of dissent suggests low near-term governance risk, which may matter for liquidity and index eligibility, but it is not enough to drive a sustained move without operating data. The contrarian point is that the market may be underestimating how little pricing power these software rollups have when public-sector and pharmacy customers delay upgrades; absent a revenue inflection, any post-AGM stability can fade into the next print.

Falsifier: if July 30 revenue shows mid-single-digit organic growth or better and management reaffirms full-year momentum, the bearish setup breaks. If growth is sub-3% or guidance language turns cautious on renewal timing, the stock likely de-rates quickly over the following 1-3 months.

Key Decisions for Investors

• No immediate trade in EQS: treat the AGM as housekeeping, not a catalyst; wait for the July 30 revenue print before taking directional risk.
• Set an alert on EQS into July 30: if the stock rallies 5-8% pre-print without data improvement, fade the move with a short-dated tactical short or put spread into the release.
• If S1 revenue implies accelerating organic growth, buy EQS on the print for a 1-3 month continuation trade; target a 10-15% upside re-rating if the market starts underestimating FY26 revenue visibility.
• If available liquidity allows, use a post-print pair: long EQS vs short a slower-growing European healthcare IT peer to isolate execution rather than sector beta; thesis fails if both names show similar backlog momentum.
• No options recommendation absent borrow/liquidity confirmation; for now, the higher-conviction action is to stay on watch for guidance revisions at the September 28 results.